Ex vivo influence of carbetocin on equine myometrial muscles and comparison with oxytocin by Steckler, Daniela
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Ex vivo influence of carbetocin on equine myometrial muscles and
comparison with oxytocin
Steckler, Daniela
Abstract: Der interzyklische Effekt von Oxytozin und Carbetozin auf die Gebärmuttermuskulatur der
Stute wurde mit Hilfe von pharmakokinetischen und pharmokodynamischen Studien untersucht. Das
komplette pharmakokinetische Profil von Oxytozin war unbekannt und musste untersucht werden. Um
das zu tun wurden 25 IU Oxytozin sechs zyklischen Stuten intravenös verabreicht und Blutproben vor
und 2, 4, 8, und 15 Minuten nach der Injektion gesammelt. Es wurde festgestellt, dass die Halb-
wertszeit von Oxytozin 5.89 Minuten, die Ausscheidungsrate 11.67 L/min, und die durchschnittliche
Verbleibzeit 7.78 Minuten betrifft. Die effektive Plasmakonzentration wurde auf 0.25 ng/mL geschätzt.
Dies stimmte überein mit der Konzentration die in der Gewebebadstudie erreicht wurde. In dieser wurde
die Konzentration die 50% des maximalen Effektes (EC50) bewirkt auf 0.45 ng/mL errechnet. Um
den interzyklischen Effekt von Oxytozin und Carbetozin zu untersuchen wurden Gebärmuttermuskel-
streifen von geschlachteten Stuten in Östrus, Diöstrus und Anöstrus gesammelt. Diese Streifen wurden
im Gewebebad montiert und vier aufsteigenden, kumulativen Konzentrationen von Oxytozin und Car-
betozin ausgesetzt. Die Fläche unter der Kurve und die Amplitude, die maximale Reaktion (Emax),
und die Konzentration die 50% des maximalen Wirkung (E50) auslöste wurden für jeden Agonisten un-
tersucht und statistisch ausgewertet. Die Wirkung von Oxytozin auf die Gebärmuttermuskulatur war
größer wahrend des Diöstrus, und überraschenderweise auch während des Anöstrus, als wahrend des
Östrus obgleich die Wirkung von Carbetozin die gleiche war, unabhängig vom Zyklus. Ein bedeutender
Unterschied wurde festgestellt für Östrus and Anöstrus wenn Oxytozin benutzt wurde aber nicht für
Carbetozin. To determine the intercyclic effect of oxytocin and carbetocin on equine myometrial tissue,
the effect of the drugs was evaluated through pharmacokinetic and pharmacodynamic studies. The com-
plete pharmacokinetic profile for oxytocin was unknown and had to be established. To do so, 25 IU of
oxytocin were administered intravenously to six cycling mares and blood samples were collected before
and 2, 4, 8, and 15 min after administration. The half-life of oxytocin was determined to be 5.89 min, the
clearance rate 11.67 L/min, mean residence time (MRT) 7.78 min. The effective plasma concentration
was estimated to be 0.25 ng/mL. This was similar to the concentration achieved for the organ bath study
where the concentration that produced 50% of the maximum effect (EC50) was calculated at 0.45 ng/mL.
To determine the intercyclic effect of oxytocin and carbetocin uterine myometrial samples were collected
from slaughtered mares in estrus, diestrus, and anestrus. The samples were mounted in organ baths
and exposed to four ascending, cumulative doses of oxytocin and carbetocin. Area under the curve and
amplitude, maximum response (Emax), and concentration that produced 50% of the maximum effect
were studied for each agonist and statistically evaluated. The effect of oxytocin on equine myometrial
tissue was higher during diestrus, and surprisingly anestrus, than during estrus, whereas the effect of
carbetocin was the same independent of the stage of estrous cycle. A significant difference was found for
estrous and anestrous samples when oxytocin was used but not when carbetocin was used.
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Abstract
To determine the intercyclic effect of oxytocin and carbetocin on equine myometrial tissue, the effect of the drugs was
evaluated through pharmacokinetic and pharmacodynamic studies. The complete pharmacokinetic profile for oxytocin was
unknown and had to be established. To do so, 25 IU of oxytocin were administered intravenously to six cycling mares and blood
samples were collected before and 2, 4, 8, and 15 min after administration. The half-life of oxytocin was determined to be 5.89
min, the clearance rate 11.67 L/min, mean residence time (MRT) 7.78 min. The effective plasma concentration was estimated to
be 0.25 ng/mL. This was similar to the concentration achieved for the organ bath study where the concentration that produced 50%
of the maximum effect (EC50) was calculated at 0.45 ng/mL. To determine the intercyclic effect of oxytocin and carbetocin uterine
myometrial samples were collected from slaughtered mares in estrus, diestrus, and anestrus. The samples were mounted in organ
baths and exposed to four ascending, cumulative doses of oxytocin and carbetocin. Area under the curve and amplitude, maximum
response (Emax), and concentration that produced 50% of the maximum effect were studied for each agonist and statistically
evaluated. The effect of oxytocin on equine myometrial tissue was higher during diestrus, and surprisingly anestrus, than during
estrus, whereas the effect of carbetocin was the same independent of the stage of estrous cycle. A significant difference was found
for estrous and anestrous samples when oxytocin was used but not when carbetocin was used.
© 2012 Elsevier Inc. All rights reserved.
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1. Introduction
Two major causes for economic losses in the equine
breeding industry are the failure of a mare to conceive
or a delay in a mare’s reconception [1,2], both of which
have shown to be caused mainly by a delayed uterine
clearance in association with reduced uterine contrac-
tility [2]. Uterine contractions are vital in the transport
of sperm through the uterus to the uterotubal junction,
as well as for the clearance of sperm after breeding, or
of accumulated intrauterine fluids [3]. A large percent-
age of mares susceptible to endometritis most likely
have intrinsic contractile defects in myometrial contrac-
tility [4]. This results in accumulation of intrauterine
fluid after breeding, predisposing the mare to persistent
mating-induced endometritis (PMIE) [4]. In the mare,
treatment of PMIE and stimulation of postpartum uter-
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ine involution [5] includes the use of oxytocin and
natural or synthetic prostaglandin F2 (PGF2), which
aid in promoting uterine clearance. Oxytocin stimulates
uterine contractions, release of arachidonic acid, and
prostaglandin formation, which in turn enhance uterine
contractions by causing membrane depolarization and
by increasing the number of gap junctions [6]. Clear-
ance of uterine contents provides a uterine environment
suitable for an embryo descending into the uterus, thus
improving conception rates.
Both oxytocin and PGF2 have disadvantages in
their application; for example, oxytocin needs to be
given in short intervals because of its short half-life (6.8
min), and PGF2 in its natural form has unwanted side
effects (sweating, tachypnea, increased gastrointestinal
motility, signs of colic) [7,8]. A drug without side
effects and a long half-life stimulating a prolonged
tocolytic effect might improve uterine clearance. The
use of carbetocin, a long acting analogue of oxytocin,
has been investigated as a beneficial form of treatment
on uterine involution in bovines [9], as well as in
humans for the treatment of postpartum hemorrhage
[10–12]. In adult, nonlactating anestrous mares carbe-
tocin has been shown to have a half-life of approxi-
mately 17 min, which is 2.5-fold longer than that of
oxytocin, and not associated with any side effects [7].
As such we believe that carbetocin may prove more
beneficial in horses in inducing parturition, decreasing
the time to conception postpartum, and aid in the treat-
ment of PMIE [13].
For the current study we investigated if the concentra-
tion-dependent contractile responses of carbetocin in
healthy estrous, diestrous, and anestrous equine myome-
trial smooth muscle were superior to that of oxytocin. The
duration of effect was extrapolated from the pharmacoki-
netic time versus concentration profile for the mentioned
oxytocin (self-generated) and carbetocin [7].
2. Materials and methods
2.1. Pharmacokinetic study
The pharmacokinetics of oxytocin was evaluated
after a single intravenous dose in adult horses.
2.1.1. Animals
Six healthy, adult, nonlactating cycling Nooitge-
dacht mares of the Veterinary Faculty were used for the
study. All animals were vaccinated and dewormed, and
kept in their usual environment. The study was ap-
proved by the Animal Use and Care Committee of the
University of Pretoria according the South African
standard for the care of laboratory animals (SANS 10
386, Project Number V026/08).
2.1.2. Sample collection and preparation
An indwelling intravenous catheter was placed into
the left jugular vein for blood sampling. The oxytocin
treatment (25 IU) (Fentocin; Virbac, Centurion, South
Africa) was administered into the opposite jugular vein
by means of a disposable syringe and a 20-gauge nee-
dle. Blood samples were collected before administra-
tion and at 2, 4, 8, and 15 min after oxytocin adminis-
tration, into chilled serum tubes containing aprotonin
(500 kallikrein inhbitor unit (kIU)/mL of blood) (Apro-
tonin; Sigma-Aldrich (Pty), Ltd., Aston Manor, South
Africa).
After collection, the blood samples were centrifuged
at 1600  g at 4 °C for 15 min and the supernatant of
each sample was transferred to a labeled polycarbonate
tube and immediately frozen at 80 °C. Hormone
assay samples were extracted using a 200 mg C18
Sep-Pak (Waters Cooperation, Milford, MA, USA) col-
umn under the following conditions: equilibration of
the column with 1 mL of acetonitrile, followed by 10 to
25 mL of 0.1% trifluoroacetic acid (TFA) in water
before application of the sample. After sample applica-
tion, the sample was washed with 10 to 20 mL of 0.1%
TFA in water, followed by a final elution with 3 mL of
acetonitrile 0.1% TFA in water (60:40). Samples were
subsequently dried under a steady stream of nitrogen at
40 °C.
Oxytocin concentrations were quantified using the
oxytocin Enzyme Immunoassay Kit (Assay Designs, Ann
Arbor, MI, USA) according to the manufacturer’s instruc-
tions. In short, 100 L of sample were pipetted into
sample wells with 50 L of both the blue conjugate
(alkaline phosphatase conjugated with oxytocin) and an-
tibody. The plates were subsequently gently mixed and
incubated at 4 °C for 18 to 24 h. After three washes with
400 L of wash solution 5 L of blue conjugate was
added into to wells with 200 L of p-nitrophenylphos-
phate in buffer (pNpp Substrate, Assay Designs, Ann
Arbor, MI, USA) and allowed to incubate at room tem-
perature for 1 h before the addition of 50 L of Stop
Solution. The 96-well plate was immediately read with an
Eliza iEMS reader MF (Labsystems, Helsinki, Finland;
wavelength range 340 to 850 nm, wavelength accuracy
2 nm) at an optical density of 405 nm with correction
between 570 and 590 nm.
2.1.3. Pharmacokinetic analysis
Noncompartmental pharmacokinetic analysis was
performed using Kinetica Version 5.0 (Thermo Fisher
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Scientific, BioImage, Soeborg, Denmark). The area un-
der the concentration-time curve to the last plasma
sampling time (AUClast) was calculated according to
the linear trapezoidal rule. The area under the concen-
tration-time curve extrapolated to infinity (AUCinf) as
AUCinf  Ct/Lz, where Ct was the last measured con-
centration and Lz was the slope of the terminal propor-
tion of the plasma versus time concentration curve
following natural logarithmic transmotion. The half-life
(t½), mean residence time (MRT), volume of distribu-
tion (l/kg) and clearance (mL/kg per min) were calcu-
lated using standard formulas.
2.2. Organ bath myometrial study
Ex vivo influence of carbetocin on equine myome-
trial muscles and comparison with oxytocin.
2.2.1. Sample preparation
Myometrial smooth muscle strips were obtained
from 16 unmated cross-breed Nooitgedacht mares in
estrus (N  5), diestrus (N  6), and anestrus (N  5)
between the age of 3 and 10 yr from a commercial
abattoir (Krugersdorp Abattoir, Krugersdorp, South Af-
rica). Stage of cycle was determined on examination of
the ovaries and plasma progesterone concentrations
(PPC). The presence of a corpus luteum and high pro-
gesterone concentration confirmed diestrus. A re-
gressing corpus luteum, a low progesterone concen-
tration, and a dominant follicle of more than 2 cm
confirmed estrus. Inactive ovaries without a domi-
nant follicle and a corpus luteum and low progester-
one concentration confirmed anestrus.
2.2.2. Sample collection
A blood sample for plasma progesterone concentra-
tions was collected in 5 mL heparin tubes during the
slaughter of the animal, centrifuged, and the superna-
tant frozen for later analysis. The entire reproductive
tract, including vagina, cervix, uterine body, uterine
horns and both ovaries, were obtained immediately
after slaughter. A 4-cm rectangular specimen was sec-
tioned from the base of each uterine horn and placed
into 4 °C cold Krebs-Henseleit solution (KHS) which
was preoxygenated for 30 min with 95% O2 and 5%
CO2 in oxygen (carbogen) to reach a pH of 7.3 to 7.4.
The KHS contained: NaCl 6.9 g/L; KCl 0.35 g/L;
NaHCO3 2.09 g/L; MgSO4 0.14 g/L; KH2PO4 0.16 g/L;
glucose 1.09 g/L; CaCl2 · 2H2O 0.28 g/L, and Na-
pyruvate 0.22 g/L and was made fresh before sample
collection (all chemicals procured from Sigma-Aldrich
(Pty), Ltd.). The samples were subsequently trans-
ported to the Faculty of Veterinary Science.
A uterine swab was taken from each mare and the
smear examined for uterine pathology, such as the
presence of neutrophils and bacteria indicating uterine
inflammation. A full thickness uterine biopsy was taken
from each mare for histopathology and evaluated ac-
cording to Kenney [14]. This system takes into consid-
eration inflammation and fibrosis of the endometrium
and provides an estimation of the mare’s ability to
conceive and maintain a pregnancy until term. The
uterus was graded: Grade I, IIA, IIB, or III. Mares with
a Grade I have a more than 80% chance of conceiving
and maintaining a pregnancy until term, whereas mares
with a Grade III are expected to only have a 10% to
50% of conceiving and maintaining a pregnancy until
term. Only mares without uterine pathology and an
endometrial biopsy score of I and IIA were included in
the study.
2.2.3. Preparation of smooth muscle specimen
After transportation to the laboratory, the 32 tissue
samples were sectioned into 5  20-mm strips in
warmed oxygenated KHS. All the prepared strips were
full thickness and cut parallel to the longitudinal muscle
fibers. The endometrium and any excess connective
tissue were dissected apart from the muscle layers using
a dissecting microscope.
2.2.4. Tissue baths
The 32 tissue samples were mounted in standard
100-mL organ baths. Each bath was filled with 50 mL
of KHS, maintained at 37 °C and continuously bubbled
with carbogen.
A force-displacement transducer attached to a chart
recorder was used to evaluate the mechanical activity of
the myometrium. Time from collection to tissue mount-
ing was approximately 90 to 100 min. Tissue strips
were allowed to equilibrate for 30 min before tension
being applied. Tissues were subsequently mounted un-
der tension of 2 g [15], whereafter they were exposed
to another 15 min of equilibration before initial stimu-
lation.
Each muscle strip was exposed to four ascending
concentration (Conc.) doses of oxytocin (0.086 [Conc.
1], 0.94 [Conc. 2], 9.5 [Conc. 3], and 52.3 ng/mL
[Conc. 4]) and carbetocin (3.5 [Conc. 1], 38.5 [Conc.
2], 388.5 [Conc. 3], and 2138 ng/mL [Conc. 4]) (V-
Tech Pharmacy, Midrand, South Africa) in a cumula-
tive concentration-response protocol. Tissues were al-
lowed 2 min to contract before ascension to the next
dose. After the response to the additive last concentra-
tion was recorded, the compound was washed from the
organ bath three times, before the subsequent assays
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were run. The tissues returned to their normal resting
phase after the washes and the experiment was contin-
ued. Needed electrolytes were supplied in the buffer
solution to avoid depletion of electrolytes. The tissues
were given time to equilibrate between responses to
return to no or initial contractility.
2.2.5. Data analysis
The amplitudes of the myometrial contractile activity
were converted to % response according the following
equation: % response  amplitude achieved after expo-
sure/highest amplitude achieved (all samples) multiplied
by 100. The maximum response (Emax) and the concen-
tration that produced 50% of the maximum effect (EC50)
were ascertained by curve fitting the dose response data to
an Emax equation (Kinetica 5, Thermo). EC50 is the con-
centration required to produce 50% of the response and
can be used for comparison between drugs to the nature of
the linear nature of pharmacodynamic (PD) graphs from
20% to 80%. The Emax is theoretically the concentration
required to produce a maximum effect and is based on
curve fitting. Due to the sigmoid nature of PD curves the
EC50 is never related in a linear manner to Emax. The
difference in response for the various cycles was evalu-
ated using an ANOVA with Tukey Honestly Significant
Difference (HSD) test and Bonferroni post hoc test.
Statistical analysis was performed with the statistical
software SPSS19 (IBM South Africa, Sandton, South Af-
rica). A Kolmogorov-Smirnov and Lilliefors table was
used to assess the normality of distribution after various
transformations. Because normality could not be demon-
strated, differences per treatment for the different cycles
were compared with a Kruskal-Wallis test and a P value
of 0.05 post hoc comparison were made between the
cycles using a Mann-Whitney test with the P value being
set at 0.025 after Bonferroni correction. Differences be-
tween the different treatments per cycle were compared
using a Mann-Whitney test at a P value of 0.05.
3. Results
3.1. Pharmacokinetic study
The plasma versus time concentration profile ob-
tained for oxytocin during the study is presented in
Figure 1. The calculated pharmacokinetic parameters
are presented in Table 1.
All the horses had baseline oxytocin concentrations
of 0.009 0.004 ng/mL. After administration oxytocin
was characterized by a mean plasma concentration of
0.51  0.01 ng/mL. The plasma concentration thereaf-
ter rapidly declined with the half-life of elimination of
5.89  0.699 per min. The drug was also characterized
by a low MRT of 7.708  1.15 min.
3.2. Organ bath myometrial study
From the 16 mares used for the study, five mares
were in estrus, six in diestrus, and five in anestrus.
Uterine swabs showed no signs of infections, while all
uterine biopsies were scored as Grade I or Grade IIA.
From each of the 16 mares, two strips of uterine tissue,
including longitudinal and circular muscle layers, were
used for the study. Of the 32 samples only 14 (44%)
showed spontaneous uterine contractions. Five of the
samples showing spontaneous contractions were ob-
tained from mares in estrus, two samples from mares in
diestrus, and seven samples from mares in anestrus.
3.2.1. EC50 values for oxytocin and carbetocin
Figure 2 shows the EC50 values (ng/mL) for oxyto-
cin and carbetocin for mares in estrus, diestrus, and
anestrus. Mean  SD for oxytocin EC50 values were
4.57  5, 3.12  4.47, 0.45  0.92 ng/mL for estrous,
diestrous, and anestrous mares. Mean  SD for carbe-
tocin EC50 values were 6.95  6.73, 10.51  13.68,
3.47 4.65 ng/mL for estrous, diestrous, and anestrous
mares.
No significant difference could be observed between
any of the estrous cycle phases for carbetocin (P 
0.79). For oxytocin a significant difference was present
between stages (P  0.007): estrus and anestrus (P 
0.008), and diestrus and anestrus (P  0.009), while no
significant difference was present between estrus and
diestrus (P  0.425). Comparison between oxytocin
and carbetocin during the different cycle stages re-
vealed a significant difference for anestrus (P  0.031)
but no significant difference for estrus and diestrus.
Figure 3 shows the effect of oxytocin on equine
myometrial tissue ex vivo at different stages of the
Fig. 1. Average plasma concentration versus time profile for horses
after intravenous administration of 25 IU oxytocin (Fentocin, Virbac,
Centurion, South Africa).
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estrous cycle. A weak relative response of estrous myo-
metrial tissue can be observed for Conc. 1 and 2.
Thereafter the relative response increases for Conc. 3
and Conc. 4 in a dose-dependent fashion. During di-
estrus, a similar myometrial response can be observed
but with an overall stronger relative response of the
myometrial tissue to oxytocin, compared with estrous
myometrial tissue. During anestrus, a dose-dependent
increase in response can be observed with increasing
concentrations, up to Conc. 3 whereafter the relative
response of the myometrial tissue stays the same or
starts to decline with Conc. 4 indicating that the max-
imum achievable effect has been reached. The mean
relative response of oxytocin shows a steady increase
with increasing drug concentrations. Figure 4 shows the
effect of carbetocin on equine myometrial tissue ex
vivo at different stages of the estrous cycle. The relative
response of estrous myometrial tissue to carbetocin is
weak for Conc. 1, stronger for Conc. 2, 3, and 4, but
with no dose-dependent increase for these concentra-
tions. A stronger relative response to carbetocin can be
observed for diestrous and anestrous myometrial tissue
compared with estrous tissue, especially in response to
Conc. 1.
The mean relative response of carbetocin shows a
dose-dependent increase up to Conc. 2, whereafter the
effect plateaus.
4. Discussion
To determine the intercyclic effect of carbetocin and
oxytocin, the effect of the drugs was evaluated through
pharmacokinetic and pharmacodynamic studies. The
effects of both drugs in organ baths were evaluated. To
determine the validity of the results, the EC50’s ob-
Table 1
Plasma pharmacokinetic parameter for oxytocin following a single intravenous injection of 25 IU to six Nooitgedacht mares.
Animal AUClast
(ng/mL  min)
AUCinf
(ng/mL  min)
Lz
(L/min)
AUMClast
(ng/mL per min2)
t1/2 (min) MRT (min) Clearance
(L/min  kg)
Vss (L/kg) Vz (L/kg)
1 5080 6020 0.12 24 300 5.84 7.68 9.14 70.25 77.07
2 3550 4430 0.10 18 400 6.44 8.97 12.40 111.24 115.27
3 4540 5340 0.12 21 500 5.77 7.55 10.29 77.70 85.70
4 3690 4640 0.10 19 700 6.63 9.26 11.83 109.61 113.25
5 3710 4320 0.11 15 400 6.02 6.94 12.70 88.25 110.44
6 3600 4010 0.14 16 100 4.64 6.26 13.70 85.78 91.81
Mean 4030 4790 0.11 19 200 5.89 7.78 11.67 90.47 98.92
Median 3700 4540 0.11 19 000 5.93 7.62 12.11 87.02 101.13
SD 630 745 0.01 3350 0.69 1.15 1.67 16.71 16.17
% CV 15.63 15.55 9.09 17.44 11.71 14.78 14.31 18.47 16.89
AUCinf, area under the concentration-time curve extrapolated to infinity; AUClast, area under the concentration-time curve to the last plasma
sampling time; AUMClast, area under the moment curve to the last sampling time; Lz, slope of the curve (slope of the linear regression of the
log-transformed concentration-time); MRT, mean residence time; t1/2, half-life of elimination; Vss, volume of distribution at steady state; Vz,
volume of distribution at the terminal stage.
Fig. 2. Effect of oxytocin and carbetocin on estrous (N  10),
diestrous (N  12), and anestrous (N  10) myometrial tissue
described as mean concentration that produced 50% of the maximum
effect (EC50) (ng/mL;  SD). Significant difference between stages
only for oxytocin: estrus and anestrus (P  0.008), diestrus and
anestrus (P  0.009).
Fig. 3. Effect of cycle stage on myometrial response to oxytocin
stimulation ex vivo (estrus N  10, diestrus N  12, anestrus N 
10,  SD).
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tained were compared with estimated effective plasma
concentration.
Because the complete pharmacokinetic profile for
oxytocin was unknown the first part of modeling was to
establish the pharmacokinetics of oxytocin. For the
current study the half-life of oxytocin in cycling, non-
pregnant mares was determined to be 5.89 min, which
differed minimally from the half-life of 6.8 min re-
ported by Paccamonti, et al. [16]. The difference in the
half-life of the two studies most likely results from the
different animals used in the two studies (Warmblood
mares vs. Nooitgedacht mares) as the difference in
body weight and metabolic capacity might affect the
clearance rate and the half-life of the drug. This result
is supported by other pharmacokinetic studies on oxy-
tocin in farm animals, where a half-life of 22.3 min was
reported in goats while the half-life in cattle, from
various studies, was approximately 7 to 9 min [17–20].
As can be seen from this study, there is an inverse
proportional relationship between body weight and the
half-life of response (i.e., the smaller animal being the
goat having the longer half-life). Another interesting
feature of oxytocin is that its metabolism appears to be
largely extrahepatic. Mitchell and coworkers found that
rat uterine tissue contains peptidase activity which de-
grades, metabolizes, and thus inactivates oxytocin.
They speculated that this mechanism could be impor-
tant in regulating the metabolism of oxytocin during
parturition [21].
As expected oxytocin was characterized by a low
MRT and a high mean volume of distribution (Vd).
Because MRT represented approximately 63% of total
time any drug spends in the body, the small value
obtained for this study was clearly related to the rapid
half-life of the drug. As an estimate the MRT was
inversely proportional to the elimination constant. The
same principle may be applied to the Vd. The Vd was
determined from the dose being administered against
the maximum plasma concentration after intravenous
administration. Because the maximum concentration
achievable was clearly related to half-life, the rapid
elimination did result in a falsely elevated Vd. How-
ever, another factor that most likely contributed to the
high Vd was the ability of oxytocin to be highly tissue-
bound and metabolized in the biophase where it was
active [21] at the level of oxytocin receptor.
To determine the validity of the results achieved
from the ex vivo study, the results were evaluated using
pharmacokinetic-pharmacodynamic modeling.
The use of ex vivo techniques to study uterine con-
tractility permits the evaluation of specific contractile
responses in tissues obtained from animals of precisely
known in vivo functional status in the absence of po-
tentially confounding interactions that might occur in
vivo [22]. Ex vivo studies on smooth muscle strips in
organ baths have served as an alternative for investiga-
tions of myometrial activity. The ex vivo assessment of
the contractility of the smooth muscle layer of the
uterus in the mare may serve as a more precise and
accurate measurement for understanding the influence
and interaction of endogenous and exogenous drugs
under in vivo conditions [15,23]. For this study, the
effect of the selected agonists on the myometrium alone
was determined, as this tissue contains the receptor
series involved with contractility.
During the initial part of the experiment, spontane-
ous contraction of equine myometrial tissue could be
observed in only 14 out 32 samples (44%). This was
markedly different from a study by Hirsbrunner and
coworkers [15], who were able to demonstrate sponta-
neous myometrial contractions of all estrous and di-
estrous circular and longitudinal myometrial tissue
samples, whereas Rigby and coworkers [23] were “sel-
dom” able to, while Ousey et al. [24] were not able to
demonstrate any spontaneous myometrial contractions.
This tends to suggest that the response of the myome-
trium is dependent on a number of factors, such as
survivability of tissue ex vivo, number of active recep-
tors, muscle activity, and individual variation.
The EC50 (amount of drug necessary to achieve 50%
of maximal contraction) was found to be highest in
estrous tissues, lower in diestrous tissues, and lowest in
anestrous myometrial tissues after oxytocin administra-
tion. Although the EC50, due to the sigmoid nature of
OD curves, is not related in a linear manner to Emax, the
effect on estrous tissue is unexpected as the results do
not follow clinical responses for the drug. The high
Fig. 4. Effect of cycle stage on myometrial response to carbetocin
stimulation ex vivo (estrus N  10, diestrus N  12, anestrus N 
10,  SD).
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EC50 of estrous tissue suggests that an increased
amount of oxytocin is needed to cause a response of the
myometrium. Expected was that, due to a high concen-
tration of oxytocin receptors within the myometrium
during estrus, a decreased amount of oxytocin is needed
to result in a myometrial response, as suggested by
literature [27]. One explanation may involve the rapid
metabolism at the level of the endometrium. This
mechanism was not considered important for this study,
as the endometrium was removed before tissue incuba-
tion. A second explanation may involve the concentra-
tion of active receptors at the level of the muscles. In
studies by Tetzke et al. [25], it was clearly demon-
strated that the myometrium receptivity for oxytocin
depends on the cycle stage. Further studies by Stull and
Evans [26] and Sharp et al. [27] have demonstrated that
the oxytocin receptors are present to a greater extent in
the myometrium than in the endometrium of nonpreg-
nant and pregnant mares. Receptor numbers have also
been shown to differ within the estrous cycle itself as
the highest concentration of receptors can be found
during early estrus (Day 14–17), compared with late
estrus (Day 18 to 0), and diestrus (Day 1–13) [27]. The
estrous tissue used in this study had been collected from
mares in advanced estrus (Day 18 to 0) during which
the receptor number has found to be lower than in early
estrus, increasing the EC50 to some degree. It raises the
question if a higher receptor concentration will result in
a higher response, and how will this be evident in the
animal in vivo? During an ex vivo study no inhibitory
systems are in place as would be in vivo, which might
influence the results. No literature could be found with
regard to the response of myometrial tissue to oxytocin
during anestrus. It is surprising that anestrous myome-
trial tissue should have a significantly lower EC50 than
estrous and diestrous tissue and thus a higher response
to oxytocin, assumingly due to a higher oxytocin re-
ceptor concentration. These results can currently not be
explained and need further investigation.
In contrast, myometrial contractility in response to
carbetocin did not appear to be affected by the stage of
the cycle. The reason for the lack of a stage-related
response by carbetocin is more difficult to explain. One
reason for the effect seen may be due to a difference in
receptor binding between oxytocin and carbetocin. The
first receptor mechanism results from the direct stimu-
lation of the myometrium via a vasopressin receptor
with subsequent activation of a calcium-controlling
second messenger system [28]. The second receptor
mechanism relies on the stimulation of oxytocin recep-
tors in the endometrium and myometrium with subse-
quent release of PGF2 and its related stimulation of
uterine contractions and luteolysis [28]. Of these two
receptor series the oxytocin receptor is cyclic (as men-
tion above) in their concentration while the vasopressin
receptor remains at a constant level [28]. In a study by
Engstrøm et al. [28] it was further demonstrated that
oxytocin had poor affinity for the vasopressin receptor
while carbetocin had affinity for both receptor series.
This would therefore explain the differences evident,
i.e., the effect of oxytocin being cyclic due to cyclic
activation of the receptor while carbetocin is able to
produce a constant effect due to the constant concen-
tration and presence of the vasopressin receptors sys-
tem [28].
Based on the pharmacokinetic profile for oxytocin
and the known effective duration of 6.8 min for the
nonpregnant mare, the effective plasma concentration
is estimated to be 0.25 ng/mL. This was similar to the
concentration achieved for the organ bath study where
the lowest EC50 was calculated at 0.45 ng/mL for
anestrous mares. When the same trend is applied to the
published carbetocin pharmacokinetic information, and
the effective duration of 17 min, the effective plasma
concentration was estimated to be 3 ng/mL. This was
once again familiar to the lowest EC50 of 3.47 ng/mL in
anestrous mares. This therefore tends to suggest that the
organ bath concentrations are relevant to the adult
horse.
4.1. Conclusions
The results suggest that the effect of oxytocin on
equine myometrial tissue is higher during diestrus, and
surprisingly anestrus, than during estrus, whereas the
effect of carbetocin seems to be the same independent
of the stage of estrous cycle. An advantage of carbeto-
cin is its longer half-life (17 min) over the half-life of
oxytocin (6 min) in the mare.
These results might be useful in the treatment of
uterine pathology, such as advanced stages of PMIE,
pyometra, as well as for induction or enhancement of
myometrial contractions during parturition.
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